United States News Todas as matérias

Alliance Resource Partners (NASDAQ:ARLP) announced on June 8, 2026, that it has entered into definitive agreements to acquire general partner and limited partner interests in AllDale Minerals III, LP and AllDale Minerals IV, LP (collectively, “AllDale III & IV”) for approximately $206.2 million.

FOX (NASDAQ:FOX) has finalized a multi-year agreement with the National Football League to serve as a broadcast partner for NFL content in Mexico.

Seaport Therapeutics (NASDAQ:SPTX) announced its financial results for the first quarter ended March 31, 2026, marking a pivotal period of transition for the Boston-based biotech as it enters the public markets.

Incyte (NASDAQ:INCY) announced today that it has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for an upfront payment of $1.25 billion.

RedHill Biopharma (NASDAQ:RDHL) announced on June 8, 2026, that it has officially commenced recognition and enforcement proceedings in South Korea to collect on a final judgment awarded by the New York Supreme Court against Kukbo.

SUNation Energy (NASDAQ:SUNE) and Suniva announced on June 8, 2026, the signing of a definitive reverse merger agreement.

Graham (NYSE:GHM) announced its financial results for the fourth quarter and full fiscal year ended March 31, 2026, marking a period of record-setting performance for the Batavia, New York-based manufacturer.

AECOM (NYSE:ACM) announced today that it has been awarded a new contract to provide comprehensive architecture and engineering (A/E) services to the U.S. Department of Homeland Security (DHS).

Pfizer (NYSE:PFE) announced on June 8, 2026, that the U.S. Food and Drug Administration (FDA) has granted an expanded indication for HYMPAVZI® (marstacimab-hncq). The therapy is now approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with hemophilia A or B, both with and without inhibitors.

Aeries Technology (NASDAQ:AERT) announced its financial results for the fiscal year ended March 31, 2026, marking a pivotal year of transformation.

AstroNova (NASDAQ:ALOT), a global leader in specialized print technology solutions, reported financial results for its fiscal 2027 first quarter ended April 30, 2026.

Lyell Immunopharma (NASDAQ:LYEL) announced on Monday that it has amended its ongoing U.S. Phase 1 clinical trial for LYL273 to a Phase 1/2 design.

Shattuck Labs (NASDAQ:STTK) announced positive top-line results from its Phase 1 clinical trial of SL-325, a novel Death Receptor 3 (DR3) blocking antibody.

Honeywell International (NASDAQ:HON) announced on Monday that it is reaffirming its full-year 2026 financial guidance as the company nears the final stages of its portfolio transformation.

Gamehaus Holdings (NASDAQ:GMHS) reported its unaudited financial results for the third quarter of fiscal year 2026, ended March 31, 2026.

American Battery Technology Company (NASDAQ:ABAT) announced today that it has successfully won its appeal with the U.S. Department of Energy (DOE) regarding the reinstatement of a competitive grant award.

Duluth Holdings (NASDAQ:DLTH) reported financial results for the first quarter of fiscal 2026, ended May 3, 2026, highlighting significant progress in operational efficiency despite a challenging retail environment.

Advanced Micro Devices (NASDAQ:AMD) announced plans to invest up to £2 billion in the United Kingdom over the next five years, a strategic move designed to accelerate AI innovation, scientific research, and technical workforce development.

Alvotech (NASDAQ:ALVO) announced on Monday that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio (vedolizumab) for intravenous administration.

LENZ Therapeutics (NASDAQ:LENZ) and Everest Medicines announced an agreement on June 8, 2026, transferring the rights to develop, manufacture, and commercialize LNZ100—marketed in the United States as VIZZ—within Greater China.

Nurix Therapeutics (NASDAQ:NRIX) announced on June 8, 2026, that it has entered into a global licensing and collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg (NX-5948).

Global oil markets faced heightened volatility on Monday as investors reacted to an escalation in regional conflict.

Artiva Biotherapeutics (NASDAQ:ARTV) has shared encouraging clinical findings for its lead therapeutic candidate, AlloNK® (AB-101), during the European Alliance of Associations for Rheumatology (EULAR) 2026 congress.

Seaport Therapeutics (NASDAQ:SPTX) announced today positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial for GlyphAgo™ (SPT-320).